A5013087961- Diabetes Treatment and Management
- Prostate Cancer Treatment and Research
- Metabolism, Diabetes, and Cancer
- Cancer, Lipids, and Metabolism
- Radiopharmaceutical Chemistry and Applications
- Pancreatic function and diabetes
- Prostate Cancer Diagnosis and Treatment
- Blood Pressure and Hypertension Studies
- Helicobacter pylori-related gastroenterology studies
- Hormonal and reproductive studies
- Diabetes Management and Research
- Pharmacology and Obesity Treatment
- Hormonal Regulation and Hypertension
- Cardiovascular Function and Risk Factors
- Diabetes and associated disorders
- Gastroesophageal reflux and treatments
- Gastric Cancer Management and Outcomes
- Eosinophilic Esophagitis
- Pharmaceutical studies and practices
- Heart Failure Treatment and Management
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Amino Acid Enzymes and Metabolism
- Bariatric Surgery and Outcomes
- Cancer, Hypoxia, and Metabolism
- Galectins and Cancer Biology
Astellas Pharma (United States)
2017-2024
Sunnybrook Health Science Centre
2017
Dana-Farber Cancer Institute
2017
Nottingham University Hospitals NHS Trust
2017
Hôpital du Saint-Sacrement
2017
Indiana University Health
2017
Indiana University – Purdue University Indianapolis
2017
AstraZeneca (United States)
2005-2016
AstraZeneca (United Kingdom)
2001-2015
AstraZeneca (Brazil)
2005-2008
Enzalutamide, a potent androgen-receptor inhibitor, has demonstrated significant benefits in metastatic and nonmetastatic castration-resistant prostate cancer. We evaluated the efficacy safety of enzalutamide hormone-sensitive cancer (mHSPC).ARCHES (ClinicalTrials.gov identifier: NCT02677896) is multinational, double-blind, phase III trial, wherein 1,150 men with mHSPC were randomly assigned 1:1 to (160 mg/day) or placebo, plus androgen deprivation therapy (ADT), stratified by disease volume...
Dapagliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, reduces hyperglycemia in patients with type diabetes mellitus (T2DM) by increasing urinary glucose excretion, and weight loss is consistent associated finding. Our objectives were to confirm dapagliflozin establish through body composition measurements whether accounted for changes fat or fluid components. This was 24-wk, international, multicenter, randomized, parallel-group, double-blind, placebo-controlled study...
Dapagliflozin, a highly selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), reduces hyperglycaemia and weight in patients with type diabetes mellitus (T2DM) by increasing urinary glucose excretion. Long-term glycaemic control, body composition bone safety were evaluated T2DM after 102 weeks dapagliflozin treatment.This randomized, double-blind, placebo-controlled study (NCT00855166) enrolled [mean: age 60.7 years; HbA1c 7.2%; mass index (BMI) 31.9 kg/m(2) ; 91.5 kg] inadequately...
Preliminary trial results showed that enzalutamide significantly improved metastasis-free survival among men who had nonmetastatic, castration-resistant prostate cancer and rapidly increasing prostate-specific antigen (PSA) levels while taking androgen-deprivation therapy. Results from the final analysis of overall have not yet been reported. In this double-blind, phase 3 trial, with (defined on basis conventional imaging a PSA doubling time ≤10 months) were continuing to receive therapy...
Dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), has been shown to improve glycaemic control, stabilize insulin dosing and mitigate insulin-associated weight gain over 48 weeks in patients whose type diabetes mellitus (T2DM) was inadequately controlled despite high doses insulin. Here the efficacy safety dapagliflozin therapy after total 104 are evaluated this population.This 24-week, randomized, placebo-controlled, double-blinded, multicentre trial followed by...
To assess the efficacy and safety of dapagliflozin as add-on therapy in patients with type 2 diabetes who were inadequately controlled a dipeptidyl peptidase-4 inhibitor or without metformin.In this 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 study 24-week blinded extension period, 432 randomized to receive 10 mg/day placebo added sitagliptin (100 mg/day) ± metformin (≥1,500 mg/day).Baseline HbA1c FPG levels 7.9% (63.0 mmol/mol) 162.2 mg/dL...
Patients with prostate cancer who have high-risk biochemical recurrence an increased risk of progression. The efficacy and safety enzalutamide plus androgen-deprivation therapy monotherapy, as compared alone, are unknown. Download a PDF the Research Summary. In this phase 3 trial, we enrolled patients had prostate-specific antigen doubling time 9 months or less. were randomly assigned, in 1:1:1 ratio, to receive (160 mg) daily leuprolide every 12 weeks (combination group), placebo...
Abstract Aims Dapagliflozin, a selective sodium‐glucose cotransporter 2 ( SGLT2 ) inhibitor, reduces hyperglycaemia in patients with type diabetes T2DM by increasing urinary glucose excretion. Owing to its mechanism of action, dapagliflozin could potentially affect the renal tubular transportation bone minerals. Therefore, markers formation and resorption mineral density BMD were evaluated after 50 weeks treatment. Methods This international, multi‐centre, randomized, parallel‐group,...
Background— There are no randomized, controlled trial data to support the benefit of β-blockers in patients with asymptomatic left ventricular systolic dysfunction. We investigated whether β-blocker therapy ameliorates remodeling Method and Results— Patients ejection fraction <40%, mild dilation, symptoms heart failure (New York Heart Association class I) were randomly assigned receive extended-release metoprolol succinate (Toprol-XL, AstraZeneca) 200 mg or 50 placebo for 12 months....
Objectives To assess the efficacy of dapagliflozin, a sodium–glucose cotransporter 2 inhibitor, for treatment individuals with type diabetes mellitus (T2 DM ) and preexisting cardiovascular disease ( CVD ). Design Randomized, double‐blind, age‐stratified (<65 ≥65), 24‐week clinical trial 28‐week extension. Setting One hundred seventy‐three centers in 10 countries. Participants Individuals (N = 964) T2 , glycosylated hemoglobin (HbA1c) 7.0% to 10.0%, documented . Intervention Dapagliflozin...
To assess the efficacy and safety of dapagliflozin, a selective sodium-glucose cotransporter 2 inhibitor, compared with placebo in patients type diabetes (T2D), documented pre-existing cardiovascular disease (CVD), history hypertension.Patients (N = 922) were randomized to receive 10 mg dapagliflozin or double-blind trial for 24 weeks, followed by 28-week extension period. In receiving insulin, insulin dose was reduced 25% at randomization. Patients stratified age, use, time from most recent...
To assess the long-term glycaemic durability, safety and tolerability of dapagliflozin versus glipizide as add-on therapies in patients with type 2 diabetes inadequately controlled by metformin alone.This was a 52-week, randomised, double-blind study (n = 406) 408), uptitrated over 18 weeks according to response maximum 10 20 mg/day, respectively, (≥ 1500 mg/day) 156-week extension period. Data 104 are reported here.In total, 53.1% completed treatment. After greater initial decrease (0-18...
To determine the efficacy of once-daily esomeprazole plus antibiotics for eradication Helicobacter pylori, to assess effect antibiotic resistance on rate, and define rate emergent resistance.Three separate randomized trials were performed in H. pylori-positive patients with a duodenal ulcer or history documented within 5 yrs: 1) (40 mg once daily), amoxicillin (1 g b.i.d.), clarithromycin (500 b.i.d.; this combination will be referred as EAC) versus daily) twice daily; EC); 2) EAC E); 3) EC...
OBJECTIVES: The aim of this study was to assess the development erosive esophagitis, gastroesophageal reflux disease (GERD) symptoms in patients without prior symptomatic or endoscopic GERD, and worsening GERD with a post hoc analysis eight double-blind prospective trials Helicobacter pylori (H. pylori) therapy 1165 patients. METHODS: Patients active past duodenal ulcer baseline esophagitis had end endoscopies 4–30 wk after completion therapy. A total 533 heartburn regurgitation scores...
Maintenance of drug efficacy and safety over the long term is important to investigate for progressive conditions like type 2 diabetes mellitus (T2DM). This study aimed evaluate whether dapagliflozin added glimepiride observed at 24 weeks was maintained 48 weeks, provide further tolerability data in patients with T2DM.This 24-week randomized, double-blind, parallel-group, placebo-controlled trial a double-blind extension period enrolled adults whose T2DM inadequately controlled [glycated...
To evaluate the safety and efficacy of dapagliflozin as add-on therapy to metformin plus sulphonylurea over 52 weeks.Patients with type 2 diabetes mellitus (T2DM) using received 10 mg/day or placebo added for weeks (24-week randomized, double-blind period 28-week extension).A total 219 patients were randomized 1 : placebo. Over weeks, glycated haemoglobin (HbA1c) fasting plasma glucose levels showed greater improvement from baseline (-0.8% -1.5 mmol/l) than (-0.1% 0.6 mmol/l). More achieved...
Few antihypertensive drugs are available in appropriate formulations for infants.We investigated candesartan cilexetil liquid suspension a 4-week, randomized double-blind dose-ranging study followed by 1-year open-label treatment phase (NCT00244621). The drug was administered at 0.05, 0.2 or 0.4 mg/kg per day 93 hypertensive children aged 1-5 years, of whom 74 had underlying renal disorders.A single-dose pharmacokinetic profile obtained 10 patients. At 4 weeks, SBP declined dose dependently...
This 4-week randomized, double blind, placebo-controlled study (N=240), 1-year open label trial (N=233), and single-dose pharmacokinetic (N=22) evaluated candesartan cilexetil (3 doses) in hypertensive children aged 6 to 17 years. Seventy-one percent were 12 years of age or older, 71% male, 47% black. Systolic (SBP)/diastolic (DBP) blood pressure declined 8.6/4.8-11.2/8.0 mm Hg with 3.7/1.8 placebo (P<.01 compared for SBP the mid high doses DBP; placebo-corrected 4.9/3.0-7.5/6.2 Hg). The...
687 Background: ENZA, a potent androgen receptor inhibitor, has demonstrated benefit in men with metastatic and nonmetastatic castration-resistant prostate cancer (CRPC). Efficacy of ENZA ADT mHSPC is unknown. Methods: ARCHES multinational, double-blind, phase 3 study (NCT02677896). Patients (pts) were randomized 1:1 to (160 mg/day) + or PBO ADT, stratified by disease volume (CHAARTED criteria) prior docetaxel therapy. Primary endpoint was radiographic progression-free survival (rPFS)...